Palvella Therapeutics
PVLA
21 hedge funds and large institutions have $3.58M invested in Palvella Therapeutics in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 19 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
28.03% more ownership
Funds ownership: 0.48% → 28.51% (+28%)
49% less funds holding
Funds holding: 41 → 21 (-20)
51% less capital invested
Capital invested by funds: $7.24M → $3.58M (-$3.67M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 19
Top Buyers
| 1 |
HVIA
Hudson Valley Investment Advisors
Goshen,
New York
|
+$156K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.9K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
+$327 |
| 5 |
BlackRock
New York
|
+$56 |
Top Sellers
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$747K |
| 2 |
Goldman Sachs
New York
|
-$332K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$177K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
-$105K |
| 5 |
Renaissance Technologies
New York
|
-$72.2K |
PVLA Hedge Fund Activity: Q2 2024 in Review
21 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2024, worth a combined $3.58M — down 51% from $7.24M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PVLA and 0 opened new positions — a net loss of 19 holders — while 7 trimmed existing stakes and 12 added.
The largest buyer was Hudson Valley Investment Advisors, adding an estimated $156K. The largest seller was Lynx1 Capital Management, cutting an estimated $747K.
- 21 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2024, down from 41 in Q1 2024.
- Funds reported $3.58M of Palvella Therapeutics stock for Q2 2024, down 51% quarter-over-quarter.
- 0 funds opened new Palvella Therapeutics positions in Q2 2024 and 19 closed out, a net change of -19 holders.
- The largest Palvella Therapeutics buyer in Q2 2024 was Hudson Valley Investment Advisors, an estimated $156K added.
- The largest Palvella Therapeutics seller in Q2 2024 was Lynx1 Capital Management, an estimated $747K sold.
Based on aggregated 13F filings for Q2 2024.